Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE demonstrates a positive outlook due to the increased assumptions for the commercial uptake of its vaccine candidate VLA15 in Europe, aligning expectations with existing U.S. market projections. Additionally, the company has reported strong immune responses after administering a third yearly booster of VLA15, which bodes well for its future performance in the market. Although there was an unexpected suspension of the Ixchiq vaccine by the FDA, the overall earnings remained in line with expectations, indicating stability amidst regulatory challenges.

Bears say

Valneva SE faces several significant risks that contribute to a negative outlook, primarily related to potential clinical and regulatory setbacks that could hinder its vaccine development efforts and market acceptance. Recent safety concerns regarding its Ixchiq vaccine have raised doubts about its competitiveness against rivals like Bavarian Nordic's chikungunya vaccine, which may further impact Valneva's market position, particularly in Europe. Additionally, the decision to eliminate US Ixchiq sales from financial models reflects expectations of limited commercial uptake, underscoring concerns about future revenue generation and profitability.

Valneva SE (VALN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.